HALIFAX, Jan. 17 /PRNewswire-FirstCall/ -- On Thursday, January 19th at 9:00 am (ET), public Canadian company MedMira Inc. (MedMira) will launch Maple Biosciences at a news conference to be held in Toronto. This new division of MedMira will bring to market the next evolution in diagnostic instruments that will displace the current 30 year old technology used to conduct routine lab tests in hospitals, laboratories, and clinics around the world. Maple Biosciences' solutions will directly impact and improve the delivery of healthcare and the patient experience. These instruments will enable faster, same day results for patients, reduced specimen collection time and amount of specimen required, increased automation in the lab, and the streamlined diagnosis of multiple conditions and diseases from a single specimen - a whole new level of diagnostic services. WHO: Mr. Stephen Sham, Chairman and CEO, MedMira Inc. Dr. Michael Thompson, Professor of Analytical Chemistry, University of Toronto Dr. Neeraj Vats, VP of Technology and Intellectual Property, MedMira Inc. WHERE: TSX Broadcast & Conference Centre The Exchange Tower 130 King Street West WHEN: Registration: 8:45 am News Conference: 9:00 am (30 minutes) Thursday, January 19, 2006 The news conference will also all be available via audio webcast and teleconference. To access the webcast please visit http://www.newswire.ca/ or enter http://w.on24.com/r.htm?e=19166&s=1&k=717CFAAB80AEFD7E6DCA0B9EAFBB602D in your web browser. In order to listen to the conference call, please either dial 800- 814-4862 for toll-free anywhere in Canada or the USA, or 416-644-3423 in the Toronto area. A replay of the news conference will be available until 23:59 EST Thursday, January 26, 2006 and may be accessed by dialing 877-289-8525 for toll-free anywhere in Canada or the USA, or 416-640-1917 in the Toronto area and entering the passcode: 21171435 followed by the number sign anytime after the call has been ended. About MedMira MedMira is the leading global manufacturer and marketer of premium rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Andrea Young, Manager, Global Marketing Communications, MedMira, T: (902) 450-1588 or or Dr. James Smith, Investor Relations, MedMira, T: (902) 450-1588 or

Copyright